Breviscapine alleviated nonalcoholic steatohepatitis and liver fibrosis by inhibiting TGF-β-activated kinase 1 and toll-like receptor 4 (TLR4) / NF-κB signaling pathway to protect the liver and prevent the further development of liver disease to HCC [31, 32]. This evidence concerns the gene TLR4 and Hepatic fibrosis.